Impact of the 13-valent pneumococcal conjugate vaccine on Streptococcus pneumoniae multiple serotype carriage |
| |
| Affiliation: | 1. Laboratory of Molecular Microbiology of Human Pathogens, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal;2. Institute for Infection and Immunity, St. George’s, University of London, London, UK;3. BUGS Bioscience, London Bioscience Innovation Centre, London, UK;4. BioISI – Biosystems & Integrative Sciences Institute, Faculdade de Ciências da Universidade de Lisboa, Lisbon, Portugal;5. Laboratory of Molecular Genetics, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal;6. Laboratory of Microbiology and Infectious Diseases, The Rockefeller University, New York, NY, USA;1. Pennsylvania Veterinary Laboratory, 2305 N Cameron Street, Harrisburg 17110, United States;2. Veterinary Diagnostic Laboratory, University of Illinois College of Veterinary Medicine, 2001 S. Lincoln Avenue, Urbana, IL 61802, United States;3. Pathobiology Department, University of Illinois College of Veterinary Medicine, 2001 S. Lincoln Avenue, Urbana, IL 61802, United States;1. Department of Health Administration and Policy, George Mason University, 4400 University Drive, Fairfax, VA 22030, United States;2. Department of Global and Community Health, George Mason University, 4400 University Drive, Fairfax, VA 22030, United States;3. Department of Public Policy, University of North Carolina, Chapel Hill, 103 Abernethy Hall, Chapel Hill, NC 27599-3435, United States;1. Field Epidemiology Training Program (FETP), National Institute of Infectious Diseases, Tokyo, Japan;2. Department of Epidemiology for Infectious Diseases, Osaka University, Graduate School of Medicine, Japan;3. Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan;4. Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan;1. United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Frederick, MD 21702, USA;2. Merck & Co., Inc., Kenilworth, NJ, USA;3. Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA;1. Department of Infectious Diseases, Medical Mycology Research Center, Chiba University, Chiba, Japan;2. Division of Infectious Diseases, Chiba Children''s Hospital, Chiba, Japan;3. Department of Pediatrics, Chiba University Hospital, Chiba, Japan;4. Department of Microbiology and Molecular Genetics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan |
| |
| Abstract: | IntroductionPneumococcal multiple serotype carriage is important for evolution of the species and to understand how the pneumococcal population is changing with vaccination. We aimed to determine the impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on multiple serotype carriage.Methods and materialsNasopharyngeal samples from fully vaccinated pneumococcal carriers (4 doses of PCV13, n = 141, aged 18–72 months) or from non-vaccinated pneumococcal carriers (0 doses of any PCV, n = 140, same age group) were analyzed. Multiple serotype carriage was evaluated by DNA hybridization with a molecular serotyping microarray that detects all known serotypes.ResultsVaccinated children had a lower prevalence of multiple serotype carriage than the non-vaccinated group (20.6% vs 29.3%, p = 0.097), and a significantly lower proportion of PCV13 serotypes (6.4% vs 38.5%, p = 0.0001). PCV13 serotypes found among vaccinated children were mostly detected as a minor serotype in co-colonization with a more abundant non-vaccine serotype. Vaccinated children were colonized by a significantly higher proportion of commensal non-pneumococcal Streptococcus spp. (58.2% vs 42.8%, p = 0.012). In vaccinated children there were significantly less non-vaccine type (NVT) co-colonization events than expected based on the distribution of these serotypes in non-vaccinated children.ConclusionsThe results suggest that vaccinated children have lower pneumococcal multiple serotype carriage prevalence due to higher competitive abilities of non-vaccine serotypes expanding after PCV13 use. This might represent an additional benefit of PCV13, as decreased co-colonization rates translate into decreased opportunities for horizontal gene transfer and might have implications for the evolution and virulence of pneumococci. |
| |
| Keywords: | Multiple serotype carriage Co-colonization Pneumococcal conjugate vaccine PCV13 Microarray |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
